Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Homophenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 4/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homophenylalanine SCHEMBL44312 | 0.93 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL130567 | 0.93 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL44311 | 0.93 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL1078733 | 0.93 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL28594537 | 0.91 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL28287974 | 0.91 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL2305748 | 0.91 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL28286602 | 0.91 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL1245414 | 0.91 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL1026468 | 0.91 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912839-B2 | Methods of treating cancer using compounds containing a vascular disrupting agent | ELLIPSES PHARMA LIMITED (GB) | 2021-02-09 | — | — | US | disclosed |
| US-20200316212-A1 | METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | ELLIPSES PHARMA LTD (GB) | 2020-10-08 | — | — | US | disclosed |
| US-10556014-B2 | Compounds containing a vascular disrupting agent | ELLIPSES PHARMA LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
| US-10201622-B2 | Tumour-targeted theranostic | THE TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2349344-B1 | MMP ACTIVATED VASCULAR DISRUPTING AGENTS | INCANTHERA LTD (GB) | 2018-12-05 | — | — | EP | disclosed |
| EP-3348282-A1 | MMP ACTIVATED VASCULAR DISRUPTING AGENTS | Incanthera Limited (GB) | 2018-07-18 | — | — | EP | disclosed |
| US-20180177886-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | ELLIPSES PHARMA LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-2481429-B1 | MMP-14 specific cleavage sequence | INCANTHERA LTD (GB) | 2018-05-09 | — | — | EP | disclosed |
| US-9956296-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9937267-B2 | Methods of treating cancer using compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2018-04-10 | — | — | US | disclosed |
| US-8927486-B2 | Compounds | INCANTHERA LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140179592-A1 | Compounds | INCANTHERA LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2481429-A2 | MMP Activated Vascular Disrupting Agents | University of Bradford (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481428-A2 | MMP activated vascular disrupting agents | University of Bradford (GB) | 2012-08-01 | — | — | EP | disclosed |
| US-20110275554-A1 | COMPOUNDS | THE UNIVERSITY OF BRADFORD (GB) | 2011-11-10 | — | — | US | disclosed |
| EP-2349344-A1 | COMPOUNDS | University of Bradford (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100168036-A1 | GROWTH FACTOR | UNIVERSITY OF BRADFORD (GB) | 2010-07-01 | — | — | US | disclosed |
| WO-2010046628-A1 | COMPOUNDS | UNIVERSITY OF BRADFORD (GB) | 2010-04-29 | — | — | WO | disclosed |
| EP-2134372-A2 | MMP ACTIVATED VASCULAR DISRUPTING AGENTS | University of Bradford (GB) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008125800-A2 | MMP ACTIVATED VASCULAR DISRUPTING AGENTS | UNIVERSITY OF BRADFORD (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316212-A1 | METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT | MMP10, MMP25, MMP26 | ALPI 1062/4885PKM 2526/4885PTGS1 386/4885 |
| US-20110275554-A1 | COMPOUNDS | ADAM17, MMP3, MMP25 | ALPI 2147/4885PKM 2732/4885PTGS1 562/4885 |
| US-10912839-B2 | Methods of treating cancer using compounds containing a vascular disrupting agent | MMP10, MMP25, MMP26 | ALPI 1062/4885PKM 2526/4885PTGS1 386/4885 |
| US-20100168036-A1 | GROWTH FACTOR | HDGF, VEGFA, PGF | ALPI 1570/4885PKM 4229/4885PTGS1 283/4885 |
| US-20180177886-A1 | Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent | MMP10, MMP25, MMP26 | ALPI 1062/4885PKM 2526/4885PTGS1 386/4885 |
| US-20140179592-A1 | Compounds | MMP9, MMP3, MMP10 | ALPI 983/4885PKM 2760/4885PTGS1 580/4885 |
| US-10556014-B2 | Compounds containing a vascular disrupting agent | MMP10, MMP11, MMP3 | ALPI 1556/4885PKM 3322/4885PTGS1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.